14 recruiting, 7 completed, 2 enrolling by invitation, 2 not yet recruiting. 29 Phase 1, 7 Phase 2.
Follow Polymyositis: new trials by email Literature Review of Polymyositis trials Research Report on Polymyositis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of BMS-986553 in Participants With Refractory Autoimmune Diseases BMS-986553 - Systemic Lupus Erythematosus, Sjögren's Disease | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 60 | 2026-10-30 | 2026-10-14 |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease LMY-922 - Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE) | Phase 1 | Not yet recruiting | Luminary Therapeutics | 94 | 2026-10-01 | 2026-07-28 |
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders Descartes-08 - Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Recruiting | Cartesian Therapeutics | 50 | 2026-01-14 | 2026-07-27 |
| A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease ALLO-329, Cyclophosphamide, Fludarabine - Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy | Phase 1 | Recruiting | Allogene Therapeutics | 66 | 2025-11-13 | 2026-11-02 |
| A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases BMS-986515, Fludarabine, Cyclophosphamide - Refractory Autoimmune Diseases | Phase 1 | Recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 125 | 2025-09-04 | 2026-07-14 |
| Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases BCMA/CD70-targetd CAR-T - Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 11 | 2025-09-01 | 2025-09-19 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. AZD5492 - Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies | Phase 1 | Recruiting | AstraZeneca | 72 | 2025-05-01 | 2026-10-19 |
| BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR-T - Inflammatory Myopathy | Phase 1 | Recruiting | iCell Gene Therapeutics | 10 | 2025-03-20 | 2026-07-20 |
| A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases CNTY-101, IL-2, Lymphodepleting Chemotherapy - Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1 | Active not recruiting | Century Therapeutics, Inc. | 6 | 2025-02-06 | 2026-01-08 |
| Mesenchymal Stem Cells Infusion in Patients With Autoimmune Diseases Mesenchymal Stem Cells, Placebo - Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Enrolling by invitation | National Institute of Blood and Marrow Transplant (NIBMT), Pakistan | 200 | 2025-02-01 | 2025-03-21 |
| Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Enrolling by invitation | Chugai Pharmaceutical | 144 | 2024-12-09 | 2026-07-17 |
| Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases CAR T cell - Lupus Erythematosus, Systemic, System; Sclerosis | Phase 1 / Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 8 | 2024-11-29 | 2025-04-11 |
| Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM) Anti-CD19 UCAR-T cells - Dermatomyositis, Juvenile, Dermatomyositis | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 18 | 2024-11-11 | 2024-11-13 |
| Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) RAY121 - Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP) | Phase 1 | Recruiting | Chugai Pharmaceutical | 144 | 2024-08-19 | 2026-07-22 |
| Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis KYV-101 - Dermatomyositis | Phase 1 | Recruiting | Stanford University | 21 | 2024-08-02 | 2025-05-21 |
| Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis CD19-targetd CAR-T - Juvenile Dermatomyositis | Phase 1 | Recruiting | Chongqing Precision Biotech Co., Ltd | 10 | 2024-07-02 | 2024-08-26 |
| Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis Itolizumab - Dermatomyositis, Adult Type | Phase 1 | Unknown | Biotech Pharmaceutical Co., Ltd. | 44 | 2023-12-30 | 2023-08-14 |
| Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease CD19 targeted CAR-T cells - SLE (Systemic Lupus), Sjogren's Syndrome | Phase 1 | Unknown | Chongqing Precision Biotech Co., Ltd | 24 | 2023-08-31 | 2023-09-28 |
| CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease anti-CD19 CAR T cell therapy - Systemic Lupus Erythematosus, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | Miltenyi Biomedicine GmbH | 24 | 2023-07-17 | 2025-09-30 |
Showing 20 of 29. Sign in to see all of them.
Dermatomyositis (29) · Lupus Erythematosus, Systemic (14) · Scleroderma, Systemic (13) · Arthritis, Rheumatoid (7) · Autoimmune Diseases (7) · Myositis (7) · Lupus Nephritis (5) · Scleroderma, Diffuse (5) · Sjogren's Syndrome (5) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (4) · Arthritis, Juvenile (4) · Arthritis (3) · Antiphospholipid Syndrome (2) · Behcet Syndrome (2)
Skin and Connective Tissue Diseases (29) · Muscular Diseases (28) · Nervous System Diseases (28) · Neuromuscular Diseases (28) · Skin Diseases (28) · Connective Tissue Diseases (27) · Musculoskeletal Diseases (27) · Myositis (22) · Immune System Diseases (19) · Autoimmune Diseases (13) · Joint Diseases (13) · Rheumatic Diseases (13) · Arthritis (10) · Cardiovascular Diseases (7)
Cyclophosphamide (2) · fludarabine (2) · CTLA-4 Antigen (1) · Denosumab (1) · Etanercept (1) · Immunotherapy, Adoptive (1) · Interleukin-2 (1) · Ipilimumab (1) · Nivolumab (1) · Platinum Compounds (1) · Sodium Chloride (1) · Specimen Handling (1) · Stem Cell Transplantation (1) · cabozantinib (1) · itolizumab (1)
Chongqing Precision Biotech Co., Ltd (4) · Amgen (2) · Chugai Pharmaceutical (2) · Allogene Therapeutics (1) · AstraZeneca (1) · Biotech Pharmaceutical Co., Ltd. (1) · Brigham and Women's Hospital (1) · Bristol-Myers Squibb (1) · Cartesian Therapeutics (1) · Century Therapeutics, Inc. (1) · Fate Therapeutics (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Fred Hutchinson Cancer Center (1) · Indiana University (1) · Johns Hopkins University (1)
United States (18) · China (6) · Germany (6) · Canada (5) · France (5) · Poland (5) · Spain (5) · Netherlands (4) · Australia (3) · Czechia (3) · Italy (3) · Japan (3) · Romania (3) · Austria (2) · Bulgaria (2)
Ann Woolfrey (1) · Anthony A Amato, MD (1) · Carol A. Wallace, MD (1) · Daehyun Yoo, MD (1) · David Fiorentino, MD, PhD (1) · Dominique Ethgen, M.D. (1) · Erik Imel, MD (1) · Eunyoung Lee, MD (1) · Everett Meyer, MD (1) · Georg Schett, Prof. Dr. med. univ. (1) · Hussein A Tawbi (1)
PMID 21688301, PMID 23434567, PMID 33258553, PMID 35470301, PMID 38172601, PMID 41501497, PMID 42177178
2018 (1), R01NS049639 (1), UM1CA186688 (1)